Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations.

MLA

Kleykamp, Bethea A., et al. “Benefit-Risk Assessment and Reporting in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.” Pain, vol. 163, no. 6, June 2022, pp. 1006–18. EBSCOhost, https://doi.org/10.1097/j.pain.0000000000002475.

APA

Kleykamp, B. A., Dworkin, R. H., Turk, D. C., Bhagwagar, Z., Cowan, P., Eccleston, C., Ellenberg, S. S., Evans, S. R., Farrar, J. T., Freeman, R. L., Garrison, L. P., Gewandter, J. S., Goli, V., Iyengar, S., Jadad, A. R., Jensen, M. P., Junor, R., Katz, N. P., Kesslak, J. P., … Wilson, H. D. (2022). Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain, 163(6), 1006–1018. https://doi.org/10.1097/j.pain.0000000000002475

Chicago

Kleykamp, Bethea A, Robert H Dworkin, Dennis C Turk, Zubin Bhagwagar, Penney Cowan, Christopher Eccleston, Susan S Ellenberg, et al. 2022. “Benefit-Risk Assessment and Reporting in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.” Pain 163 (6): 1006–18. doi:10.1097/j.pain.0000000000002475.